Curis, Inc (NASDAQ: CRIS) stock dropped by a margin of 36.83% to finally settle at $8.01. This company speaks out about its ongoing Phase 1/2 open-label trial of a novel inhibitor known as CA-4948. The substance targets patients who are struggling with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The company pronounced the updated data at the European Hematology Association 2021 Virtual Congress (EHA).
President and Chief Executive Officer of Curis James Dentzer admit that they have been focusing on a series of mature data sets, and they happen to be quite impressed with the CA-4948 monotherapy and its associated clinical activity that continues showcasing steady progression. He terms the persons set to benefit from the trial as a “pretty hard to treat population” but expresses optimism that their efforts won’t be in vain considering the success they continue to witness with the trials.
Dentzer believes that the updated data helps build trust among patients by serving as further evidence of CA-4948’s effectiveness. He projects that impressive data will uphold patients’ reliance on the drug longer. He applauds the drug outlining that it is associated with an impeccable safety and durability profile. The studies continue evaluating additional data and backfilling cohorts, and impressive perspectives have come to light. For example, it is becoming clearer from the Phase 2 studies that the optimal dosage is 300mg BID.
Mr. Dentzer seems rather impressed with the various outcomes that they continue coming across, pointing out specifically to patients struggling with spliceosome or FLT3 mutations. He speaks out about the objective response that the three patients with the spliceosome mutation achieved. He added adding that they will continue doing anything it takes towards ensuring the best outcomes are achieved.
A lead investigator in the study Guillermo Garcia-Manero shares his views. He says that it isn’t new to him the frustrations that high-risk MDS or AML patients experience. He considers the data coming out of the study to be a spring of hope for a patient segment that almost lost hope in ever finding a working solution.